New EMA approval: Nivolumab plus Cabozantinib for advanced renal clear cell carcinoma

Bull Cancer. 2021 Sep 16:S0007-4551(21)00294-0. doi: 10.1016/j.bulcan.2021.05.005. Online ahead of print.NO ABSTRACTPMID:34538614 | DOI:10.1016/j.bulcan.2021.05.005
Source: Bulletin du Cancer - Category: Cancer & Oncology Authors: Source Type: research